Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | MARK3 | P27448 | 1/20 | 0.50 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.50 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22468928 | 0.84 | KMT2A (0.49) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL121793 | 0.82 | PTGS1 (0.41) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL27257521 | 0.81 | L3MBTL1 (0.53) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL30620463 | 0.81 | L3MBTL1 (0.50) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL28558504 | 0.81 | L3MBTL1 (0.57) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL23496956 | 0.81 | L3MBTL1 (0.53) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL30719630 | 0.81 | L3MBTL1 (0.53) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL145542 | 0.80 | PTGS1 (0.45) | HTTKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL7498775 | 0.79 | PTGS2 (0.38) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL31070592 | 0.78 | L3MBTL1 (0.47) | L3MBTL1PIM1MARK3MAP4K2CAMK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102325753-B | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2014-09-10 | — | — | CN | disclosed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| CN-1204121-C | 1,4-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2005-06-01 | — | — | CN | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| CN-1253547-A | 1,4-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2000-05-17 | — | — | CN | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | L3MBTL1 690/4885PIM1 2604/4885MARK3 1342/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | L3MBTL1 876/4885PIM1 3989/4885MARK3 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.